Cheaper Ozempic launching on 27 July 2026
Novo Nordisk is launching an authorised copy of Ozempic in South Africa on 27 July 2026 — the first authorised semaglutide copy registered by SAHPRA. It’s called Extensior. Unlike a generic, an authorised copy is made by Novo Nordisk itself using the identical active ingredient, manufacturing process, and pen device as Ozempic, just under a […]
iDexis Seeks Leave to Appeal in Compounded GLP-1 Court Battle
Pretoria compounding pharmacy iDexis, trading as Sentra Pharmacy, has applied for leave to appeal the High Court order that stopped it from manufacturing and selling compounded medicines containing semaglutide.
SAHPRA warns of criminal syndicates behind illicit online GLP-1 sales
South Africa’s medicines regulator says weight-loss injections are now the single biggest category in its investigations into illicit medicine sales. Criminal syndicates are exploiting demand for GLP-1 medicines by selling falsified or unregistered products through social media and unauthorised online channels.
What the July 2026 SA GLP-1 market shift means for patients — a summary
Generic and lower-cost semaglutide options from Sun Pharma and Novo Nordisk/Acino are entering the South African market just as regulators intensify enforcement against unregistered compounded products. Here is what it means for patients.
Aspen Pharmacare secures Canadian approval for generic semaglutide — SA manufacturing base to produce
Durban-based Aspen Pharmacare has received regulatory approval from Health Canada to distribute Aspen-Semaglutide, a generic alternative to Novo Nordisk’s Ozempic. South Africa will manufacture the multi-dose pens while a French facility produces single-dose autoinjectors — though supply chain issues may delay the Canadian launch until late October 2026.
SAHPRA reviewing 12 generic semaglutide applications
South Africa’s health products regulator (SAHPRA) said on Tuesday, July 21, that it is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy. Approval of these applications could bring lower-cost alternatives to South Africa and intensify competition in the fast-growing GLP-1 market currently dominated by Novo Nordisk […]
Novo Nordisk launches lower-cost Ozempic alternative “Extensior” in South Africa via Acino partnership
Novo Nordisk is partnering with Swiss pharma company Acino to launch “Extensior” — a lower-cost version of Ozempic — in South Africa on 27 July 2026, available in 0.25mg, 0.5mg and 1mg doses using the same injection device as Ozempic.
FDA moves to permanently ban large-scale compounded GLP-1s — what it means for South African patients sourcing from the US
The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, effectively closing the last legal pathway for large-scale compounded GLP-1 production. The public comment period closed 29 June 2026.
Novo Nordisk wins Gauteng High Court interim order against iDexis — appeal now underway
Novo Nordisk secured an interim order from the Gauteng High Court in June 2026 preventing iDexis from manufacturing and selling compounded semaglutide. iDexis is now appealing this order alongside related SAHPRA and SAPC decisions.
SAHPRA approves Sun Pharma generic semaglutide — SA becomes second market after India
SAHPRA has approved Sun Pharma’s generic semaglutide injection, a biosimilar equivalent of Ozempic, for adults with type 2 diabetes. South Africa is only the second market after India to receive this approval, with launch expected imminently.